Dashboard
1
With a growth in Net Profit of 232.83%, the company declared Very Positive results in Mar 26
- The company has declared positive results for the last 3 consecutive quarters
- ROCE(HY) Highest at 7.14%
- INTEREST COVERAGE RATIO(Q) Highest at 51,050.15
- RAW MATERIAL COST(Y) Fallen by -17.06% (YoY)
2
With ROE of 6.61%, it has a very attractive valuation with a 0.68 Price to Book Value
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-0.61%
0%
-0.61%
6 Months
5.92%
0%
5.92%
1 Year
9.67%
0%
9.67%
2 Years
48.7%
0%
48.7%
3 Years
-4.74%
0%
-4.74%
4 Years
33.61%
0%
33.61%
5 Years
8.84%
0%
8.84%
Sichuan Goldstone Asia Pharmaceutical, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
2.65%
EBIT Growth (5y)
25.43%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.09
Sales to Capital Employed (avg)
0.42
Tax Ratio
12.16%
Dividend Payout Ratio
25.03%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
8.81%
ROE (avg)
5.07%
Valuation key factors
Factor
Value
P/E Ratio
21
Industry P/E
Price to Book Value
1.36
EV to EBIT
16.81
EV to EBITDA
11.82
EV to Capital Employed
1.43
EV to Sales
2.91
PEG Ratio
0.10
Dividend Yield
0.45%
ROCE (Latest)
8.53%
ROE (Latest)
6.61%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
331.50
329.90
0.48%
Operating Profit (PBDIT) excl Other Income
124.00
60.70
104.28%
Interest
0.20
0.40
-50.00%
Exceptional Items
1.50
2.10
-28.57%
Consolidate Net Profit
115.70
33.70
243.32%
Operating Profit Margin (Excl OI)
374.20%
104.50%
26.97%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is 0.48% vs 52.17% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 243.32% vs 10.13% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
1,028.70
1,092.50
-5.84%
Operating Profit (PBDIT) excl Other Income
241.60
231.20
4.50%
Interest
1.90
1.50
26.67%
Exceptional Items
7.00
-0.30
2,433.33%
Consolidate Net Profit
128.60
88.60
45.15%
Operating Profit Margin (Excl OI)
132.60%
114.10%
1.85%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -5.84% vs -8.80% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 45.15% vs -26.59% in Dec 2024
About Sichuan Goldstone Asia Pharmaceutical, Inc. 
Sichuan Goldstone Asia Pharmaceutical, Inc.
Miscellaneous
No Details Available.
Company Coordinates 
No Company Details Available






